Research view
Switch to patient viewMyeloproliferative neoplasms: trials that stopped early
Trials on Myeloproliferative neoplasms that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
31 stopped trials give a reason in the registry, latest registry update first.
Terminated
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
Reason given in the registry “FDA Clinical Hold”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Nov 2026.
- Ended
- Oct 2026
- Phase
- Phase 1
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT02530034
Terminated
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Reason given in the registry “PI and Sponsor decision. Accrual was low and there was sufficient data to detect a response.”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Oct 2026.
- Ended
- Mar 2025
- Phase
- Phase 2
- Run by
- University of Utah
- Registry record
- NCT03627403
Withdrawn
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Reason given in the registry “PI request”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Oct 2026.
- Ended
- Jun 2026
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT06597734
Terminated
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Sept 2026.
- Ended
- Jun 2026
- Phase
- Phase 2
- Run by
- Ryvu Therapeutics SA
- Registry record
- NCT06397313
Withdrawn
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
Reason given in the registry “FDA requested significant changes to the study protocol”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Aug 2026.
- Phase
- Phase 1/2
- Run by
- Thomas Jefferson University
- Registry record
- NCT07387354
Withdrawn
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
Reason given in the registry “In alignment with company strategic direction.”
Quoted unchanged from ClinicalTrials.gov; record updated 31 Jul 2026.
- Phase
- Phase 4
- Run by
- PharmaEssentia
- Registry record
- NCT06290765
Terminated
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Reason given in the registry “No longer a research question to answer.”
Quoted unchanged from ClinicalTrials.gov; record updated 20 May 2026.
- Ended
- May 2026
- Run by
- Masonic Cancer Center, University of Minnesota
- Registry record
- NCT01962636
Terminated
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Reason given in the registry “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 May 2026.
- Ended
- May 2025
- Phase
- Phase 2
- Run by
- Fred Hutchinson Cancer Center
- Registry record
- NCT03246906
Terminated
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Reason given in the registry “The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice daily), but was closed early due to slow enrollment and changing treatment landscape moving towards less intense approaches.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Apr 2026.
- Ended
- Feb 2025
- Phase
- Phase 1/2
- Run by
- Ohio State University Comprehensive Cancer Center
- Registry record
- NCT03878199
Withdrawn
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Reason given in the registry “Drug Source Request”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Feb 2026.
- Phase
- Phase 1/2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT06284460
Terminated
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
Reason given in the registry “Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Jan 2026.
- Ended
- Dec 2025
- Phase
- Phase 1/2
- Run by
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Registry record
- NCT06245941
Terminated
Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Reason given in the registry “Did not advance to Phase 2”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Dec 2025.
- Ended
- Jan 2025
- Phase
- Phase 1
- Run by
- H. Lee Moffitt Cancer Center and Research Institute
- Registry record
- NCT05127174
Terminated
P1101 in Treating Patients With Myelofibrosis
Reason given in the registry “Study drug became commercially available”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Oct 2025.
- Ended
- Nov 2023
- Phase
- Phase 2
- Run by
- Mayo Clinic
- Registry record
- NCT02370329
Terminated
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Reason given in the registry “The study was terminated due to futility.”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2025.
- Ended
- Nov 2024
- Phase
- Phase 3
- Run by
- Incyte Corporation
- Registry record
- NCT04551066
Terminated
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Reason given in the registry “The study was terminated due to futility.”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Oct 2025.
- Ended
- Aug 2024
- Phase
- Phase 3
- Run by
- Incyte Corporation
- Registry record
- NCT04551053
Terminated
TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
Reason given in the registry “This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Aug 2025.
- Ended
- Aug 2025
- Phase
- Phase 1
- Run by
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Registry record
- NCT06388759
Terminated
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Reason given in the registry “Sponsor Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Aug 2025.
- Ended
- Aug 2024
- Phase
- Phase 1/2
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT04097821
Terminated
Connect® Myeloid Disease Registry
Reason given in the registry “Business objectives have changed”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Jul 2025.
- Ended
- Oct 2024
- Run by
- Celgene
- Registry record
- NCT01688011
Terminated
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
Reason given in the registry “Low accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Jul 2025.
- Ended
- Jul 2024
- Phase
- Phase 2
- Run by
- Weill Medical College of Cornell University
- Registry record
- NCT04103645
Terminated
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
Reason given in the registry “The study was stopped due to a business decision.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2025.
- Ended
- May 2024
- Phase
- Phase 2
- Run by
- NS Pharma, Inc.
- Registry record
- NCT04854096
Withdrawn
A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis
Reason given in the registry “0 participant accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 22 May 2025.
- Ended
- May 2025
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT06619522
Terminated
Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
Reason given in the registry “Terminated - alignment of strategic priorities”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Apr 2025.
- Ended
- Mar 2025
- Phase
- Phase 1
- Run by
- Blueprint Medicines Corporation
- Registry record
- NCT05609942
Terminated
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Reason given in the registry “Slow accrual.”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Dec 2024.
- Ended
- Nov 2023
- Phase
- Phase 3
- Run by
- Celgene
- Registry record
- NCT03755518
Withdrawn
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Reason given in the registry “Lack of funding”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Dec 2024.
- Ended
- Jun 2026
- Phase
- Phase 1
- Run by
- Leland Metheny
- Registry record
- NCT03939585
Terminated
Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
Reason given in the registry “Closed by Sponsor”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2024.
- Ended
- Apr 2024
- Phase
- Phase 1
- Run by
- Joseph Jurcic
- Registry record
- NCT05524857
Terminated
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Reason given in the registry “Company Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 31 Jan 2024.
- Ended
- Jan 2024
- Phase
- Phase 1
- Run by
- Prelude Therapeutics Incorporated
- Registry record
- NCT05107856
Withdrawn
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
Reason given in the registry “Despite several attempts to recruit eligible participants and major protocol amendments to increase the recruitment rate, recruitment challenges remained. Therefore, the Sponsor has made the decision to terminate the KER047-IR-202 Study globally.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Nov 2023.
- Ended
- Jan 2026
- Phase
- Phase 2
- Run by
- Keros Therapeutics, Inc.
- Registry record
- NCT05927012
Withdrawn
Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms
Reason given in the registry “PI discretion”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Oct 2023.
- Ended
- Oct 2024
- Phase
- Phase 1/2
- Run by
- Case Comprehensive Cancer Center
- Registry record
- NCT04629651
Withdrawn
A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN
Reason given in the registry “Samus Therapeutics Closure”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Nov 2022.
- Ended
- Feb 2024
- Phase
- Phase 2
- Run by
- Samus Therapeutics, Inc.
- Registry record
- NCT05612633
Withdrawn
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Reason given in the registry “Medigene transfered all rights to a new Sponsor”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2021.
- Ended
- Jul 2025
- Phase
- Phase 1
- Run by
- Medigene AG
- Registry record
- NCT04464889
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.